<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559363</url>
  </required_header>
  <id_info>
    <org_study_id>KD019-101</org_study_id>
    <nct_id>NCT01559363</nct_id>
  </id_info>
  <brief_title>A Safety, Pharmacokinetic &amp; Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <official_title>A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 ((Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety, plasma pharmacokinetics, and&#xD;
      maximum tolerated dose (MTD) of KD019 when administered to subjects with ADPKD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1:&#xD;
&#xD;
        -  Primary purpose is to determine the safety of KD019.&#xD;
&#xD;
        -  Dosing is for 28 days daily. After the 28-day treatment period, subjects will, at the&#xD;
           discretion of the investigator, continue to receive study treatment for 24 months from&#xD;
           their first dose or until the development of unacceptable toxicity, noncompliance, or&#xD;
           withdrawal of consent by the subject, or investigator decision. Subjects may continue&#xD;
           beyond 24 months at the discretion of the investigator after consultation with the&#xD;
           medical monitor.&#xD;
&#xD;
        -  All participants receive active KD019 study drug.&#xD;
&#xD;
        -  KD019 is an oral once daily tablet. Tablets are 50 mg, 100 mg and 150 mg in strength.&#xD;
           Participants will enroll into three sequential dosing cohort levels (50 mg, 100 mg and&#xD;
           150 mg.). Participants in Phase 1b will have their dose increased or decreased to the&#xD;
           MTD.&#xD;
&#xD;
        -  Study participants will have MRI of the abdomen (kidneys) at Screening and 6 months&#xD;
           thereafter to explore effects of KD019.&#xD;
&#xD;
        -  Echocardiogram will be performed at Screening, Day 28, months 3 and 6 and every 6 months&#xD;
           thereafter.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
        -  Primary purpose is to compare the annualized change in glomerular filtration rate (GFR)&#xD;
           in subjects with ADPKD when treated with KD019.&#xD;
&#xD;
        -  Two alternate dosing schedules will be explored to determine if they are more tolerable&#xD;
           than daily dosing when used chronically in subjects with ADPKD.&#xD;
&#xD;
        -  Subjects will receive study treatment for 24 months from their first dose or until the&#xD;
           development of unacceptable toxicity, noncompliance, or withdrawal of consent by the&#xD;
           subject, or investigator decision. Subjects may continue beyond 24 months at the&#xD;
           discretion of the investigator after consultation with the sponsor.&#xD;
&#xD;
        -  All participants receive active KD019 study drug.&#xD;
&#xD;
        -  Tablets are 50 mg, 100 mg, and 150 mg in strength.&#xD;
&#xD;
        -  Study participants will have MRI of the abdomen (kidneys) at Screening and Month 6 visit&#xD;
           and every 6 months after to explore effects of KD019.&#xD;
&#xD;
        -  Echocardiogram will be performed at Screening, Day 28, and Months 3 and 6 and 6 months&#xD;
           thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 8, 2019</completion_date>
  <primary_completion_date type="Actual">February 8, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, Plasma Pharmacokinetics and Maximum Tolerated Dose of KD019</measure>
    <time_frame>24 months</time_frame>
    <description>Phase 1b: Determine the safety, plasma pharmacokinetics and maximum tolerated dose (MTD) of KD019 when administered in subjects with ADPKD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Phase 2a: Evaluate the annualized change in glomerular filtration rate (GFR) in subjects with ADPKD when treated with KD019</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Kidney Volume</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the annualized percent change from baseline in total kidney volume (TKV) in subjects with ADPKD treated with KD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the annualized change from baseline in the reciprocal of serum creatinine in subjects with ADPKD treated with KD019</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, Tolerability, and Pharmacokinetics of an Alternative Dosing Schedule</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the safety profile, tolerability, and pharmacokinetics in subjects with ADPKD treated with KD019 on an alternative dosing schedule. Documentation of the number and type of adverse events related to KD019 when administered to subjects with ADPKD.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Polycystic Kidney, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Monday, Wednesday, Friday</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday, Wednesday and Friday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a Monday and Thursday</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday and Thursday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a, 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a, 50mg (SILK Cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD019 (tesevatinib)</intervention_name>
    <description>KD019 (tesevatinib) administered orally once daily.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Phase 2a Monday and Thursday</arm_group_label>
    <arm_group_label>Phase 2a Monday, Wednesday, Friday</arm_group_label>
    <arm_group_label>Phase 2a, 50mg</arm_group_label>
    <arm_group_label>Phase 2a, 50mg (SILK Cohort)</arm_group_label>
    <other_name>XL647</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a confirmed diagnosis of ADPKD.&#xD;
&#xD;
          -  The subject has a GFR ≥ 35 mL/min/1.73 m2.&#xD;
&#xD;
          -  Cysts must be at least 1 cm in size.&#xD;
&#xD;
          -  Adequate bone marrow, kidney, and liver function.&#xD;
&#xD;
          -  Must agree to use two forms of birth control for those of child bearing potential&#xD;
&#xD;
          -  Normal amylase and lipase levels&#xD;
&#xD;
          -  The subject has a htTKV ≥ 1000 mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has had a previous partial or total nephrectomy.&#xD;
&#xD;
          -  The subject has tuberous sclerosis, Hippel-Lindau disease, or acquired cystic disease.&#xD;
&#xD;
          -  The subject has congenital absence of one kidney and/or need for dialysis.&#xD;
&#xD;
          -  Presence of renal or hepatic calculi (stones) causing symptoms.&#xD;
&#xD;
          -  The subject has received any investigational therapy within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Active treatment (within 4 weeks of study entry) for urinary tract infection.&#xD;
&#xD;
          -  Subject is known to be immunocompromised&#xD;
&#xD;
          -  Subject is pregnant or nursing&#xD;
&#xD;
          -  History of pericardial effusion or presence of pericardial effusion on screening&#xD;
             echocardiogram&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  History of pancreatitis or has known risk factors for pancreatitis&#xD;
&#xD;
          -  Subject has received EGFR inhibitor at any time&#xD;
&#xD;
          -  The subject is aphakic due to previous cataract surgery or congenital anomaly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia - Nephrology Clinical Research Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <disposition_first_submitted>October 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 29, 2020</disposition_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>XL647</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

